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Abstract
It is well-established that there is a strong genetic contribution to the aetiology of attention deﬁcit hyperactivity
disorder (ADHD). Here, we employed a hypothesis-free genome-wide association study (GWAS) design in a sample of
480 clinical childhood ADHD cases and 1208 controls to search for novel genetic risk loci for ADHD. DNA was
genotyped using Illumina’s Human Inﬁnium PsychArray-24v1.2., and the data were subsequently imputed to the 1000
Genomes reference panel. Rigorous quality control and pruning of genotypes at both individual subject and single
nucleotide polymorphism (SNP) levels was performed. Polygenic risk score (PGRS) analysis revealed that ADHD
case–control status was explained by genetic risk for ADHD, but no other major psychiatric disorders. Logistic
regression analysis was performed genome-wide to test the association between SNPs and ADHD case–control status.
We observed a genome-wide signiﬁcant association (p= 3.15E−08) between ADHD and rs6686722, mapped to the
Tenascin R (TNR) gene. Members of this gene family are extracellular matrix glycoproteins that play a role in neural cell
adhesion and neurite outgrowth. Suggestive evidence of associations with ADHD was observed for an additional 111
SNPs (⩽9.91E−05). Although intriguing, the association between DNA variation in the TNR gene and ADHD should be
viewed as preliminary given the small sample size of this discovery dataset.
Introduction
Attention deﬁcit hyperactivity disorder (ADHD) is the
most commonly diagnosed neurodevelopmental disorder
of childhood. It is typically characterised by a persistent
pattern of inattention, impulsivity and/or hyperactivity.
Longitudinal studies indicate that approximately 66–77%
of individuals who experience childhood ADHD continue
to experience at least subthreshold symptoms of ADHD
that signiﬁcantly impact adulthood functioning1,2. The
global prevalence of ADHD has been estimated at
5.2–7.2%3,4. Although the aetiology of ADHD is not well
deﬁned, genetic and environmental factors have been
implicated in the disorder. Despite minor disparities
across individual samples and study designs, the overall
heritability of ADHD is estimated at 70–90%5,6.
The efﬁciency of indirect dopamine agonists in reducing
the symptoms of ADHD led to the development of the
‘dopamine hypothesis of ADHD’, which postulated that
dysregulated dopamine signalling is central to the
pathophysiology of ADHD7. Putative disruption of other
monoamines such as noradrenaline and serotonin in
ADHD has also been proposed. Accordingly, genetic
markers mapped to these monoamine pathways have
historically been pursued as candidate genes for ADHD.
Although a number of replicated ﬁndings exist within this
candidate gene literature8,9, a key limitation remains the a
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priori selection of genes based upon incomplete knowl-
edge of the biology of ADHD, which may ultimately
impede the identiﬁcation of novel risk markers.
Genome-wide association studies (GWAS) allow the
identiﬁcation of novel risk variants without prior knowl-
edge of the biology of a trait or disorder. Further, this
approach is aligned with the polygenic nature of complex
disorders whereby the small role of individual single
nucleotide polymorphisms (SNPs) can be considered in
aggregate to better understand how genetic susceptibility
may arise. To date, 13 ADHD–GWAS have been pub-
lished. Of these, seven were case–control studies10–16, two
were family-based analyses17,18, and three examined the
association between quantitative ADHD symptom mea-
sures and genetic markers19–21. A GWAS meta-analysis
was also performed in 2010 22. Overall, these previous
ADHD–GWAS had limited success in identifying asso-
ciations. However, preliminary evidence of associations
(albeit below GWAS signiﬁcance) were identiﬁed for
genes that function in biological processes relevant to
ADHD aetiology. For example, pathway analysis high-
lights a potential role for potassium channel genes and
activation Ras Homologue Family Member A (RhoA)
signalling genes, lending further support to hypothesised
dysregulation of neurotransmitter release in ADHD23.
Additional pathway analysis utilising data arising from ﬁve
ADHD–GWAS using the Ingenuity and BiNGO tools,
showed signiﬁcant enrichment of genes mapped to a
network involved in neurite outgrowth whose targets are
modulated by drugs used to treat ADHD24. Most recently,
a large meta-analysis of GWAS data arising from 20,183
ADHD cases and 35,191 controls yielded the ﬁrst 12
independently signiﬁcant ADHD–GWAS loci25.
Here, we conducted a GWAS on a rigorously diagnosed
clinical ADHD cohort collected across Australia, England
and Ireland in an attempt to clarify further the genetic
architecture of ADHD and to potentially identify novel
genetic risk factor(s). An additional important purpose of
the current study was to contribute to the expansion of
the international GWAS community. In this context,
GWAS data derived from this study can be combined
with those of the international ADHD–GWAS commu-
nity (e.g., ADHD–PGC) for subsequent GWAS analyses.
Materials and methods
Participants
Five hundred and sixty seven (N= 567) children with
ADHD of European ancestry were recruited from Aus-
tralia, the United Kingdom and Ireland. None of the
ADHD probands were included in previously published
GWAS. All cases met the DSM-IV diagnostic criteria for
ADHD at the time of sample collection. ADHD status was
determined through parental semi-structured interview
and completion of the Conners’ Parent Rating Scale for
ADHD, which has demonstrated internal reliability and
criterion validity for use in assessing ADHD26. Children
with an IQ less than 70 as determined using the Wechsler
Intelligence Scale for Children version 4 (WISC-IV
Standardisation Sample, 2003)27 were excluded. One
thousand two hundred and ninety-six control (N= 1296)
participants were also recruited. All patients and controls
were European by descent based on self-report ethnicity
of all four grandparents28. All control participants were
recruited in Australia and had no self-reported personal
history of psychiatric or neurological disorders including
ADHD. Written informed consent was provided by the
individual in the case of adults, or the primary caregiver or
guardian in the case of children/adolescents.
DNA genotyping and quality control
DNA samples were genotyped using the Illumina Inﬁ-
nium PsychArray-24v1.2 BeadChip at Path West’s Diag-
nostic Genomics Laboratory in Western Australia. The
Illumina Psych-Chip has a backbone of 510,000 markers
comprising 265,000 tagging SNPs found on the Inﬁnium
Core-24 BeadChip and 245,000 markers from the Inﬁ-
nium Exome-24 BeadChip. It was developed in colla-
boration with the Psychiatric Genomics Consortium
(PGC) and supplemented with an additional ~50,000
SNPs implicated in psychiatric and neurodevelopmental
disorders. To avoid spurious GWAS ﬁndings, we adopted
a stringent quality control (QC) protocol using PLINK
1.9 software at both the individual subject and SNP
level29,30.
Subject-level QC
The following subject-level QC was employed: (1) We
initially removed individuals with low-genotyping score
by excluding participants with ⩾0.03 of missing data; (2)
we performed identity by descent analysis to detect and
remove possible sample contaminations, duplications as
well as unknown familial relationships (such as related-
ness); (3) we applied principal components analysis to
identify any potential sources of population stratiﬁcation
and removed outlier subjects; (4) we tested for unusual
heterozygosity, which refers to the presence of more or
less heterozygous SNPs across the genome than would be
expected by the population mean, and removed indivi-
duals displaying outlying mean heterozygosity (greater
than ±3 SDs from the sample mean); and (5) disparities
between recorded and observed sex status were deter-
mined through X-chromosome homozygosity were
removed.
Following the above rigorous QC, 480 ADHD probands
(Australians= 365, English= 62 and Irish= 53) remained
in the ﬁnal set for analysis. All children were aged
between 5 and 18 years (age mean; AgeM= 10.27 years,
AgeSD= 3.03). Of the ADHD cases 87% were male and
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13% were female. The high frequency of male participants
in the ADHD cohort is reﬂective of the sex ratio in clinical
populations31. For controls, 1208 participants aged
between 7 and 60 years (AgeM= 20.61 years, AgeSD=
6.76) were carried forward to the ﬁnal statistical associa-
tion analysis. Of these participants, 49% were male and
51% were female.
SNP-level QC
Prior to imputation, additional ﬁltering steps were
conducted by removing 3516 SNPs with genotyping call
rate <95. In addition, genotyped SNPs departing from
Hardy–Weinberg (H–W) equilibrium were also excluded.
This resulted in the removal of 76 SNPs. A further 1855
SNPs with signiﬁcantly different (p ≤ 1.0E−5) missing
genotype rates between cases and controls were also
removed. Finally, SNPs with a minor allele frequency
(MAF) < 0.01 were removed leaving 290,265 in the ﬁnal
set taken forward to imputation.
DNA imputation
The freely available software packages MaCH and
Minimac2 were used for phasing and genotype imputa-
tion employing the 1000 Genomes reference panel (hg 19
build 37)32,33. Finally, a MAF⩾ 0.05 was implemented for
our ﬁnal association analysis. These constraints yielded a
ﬁnal set of 5,407,269 SNPs which were subjected to sta-
tistical association analysis.
PGRS calculation
Polygenic risk scores (PGRS) for the ﬁve major psy-
chiatric disorders including ADHD, autism spectrum
disorder (ASD), schizophrenia (SCZ), bipolar disorder
(BD) and major depressive disorder (MDD) were calcu-
lated using PRSice software package34. PGRS for each
subject and disorder were estimated as a sum of risk
alleles weighted by their effect size as deﬁned by data
arising from the latest publically available GWAS25,35–38.
For each disorder PGRS were calculated at a 1000 p
thresholds (pT) ranging from 0.0005 to 0.5. To ﬁnd the
most predictive pT logistic regression was applied at each
threshold using ADHD status as a regressor and
Nagelkerke’s R2 and the corresponding p values were
estimated. Analysis of PGRS here served to demonstrate
that the current ADHD cohort replicated the published
and publically available genetic risk proﬁle for ADHD.
ADHD case–control genome-wide association analysis
Association analysis was performed in 480 ADHD cases
and 1208 controls using logistic regression analysis
implemented in PLINK 1.9. The following covariates were
included: age, age2, age × gender, and the top ﬁve eigen-
vectors accounting for population stratiﬁcation.
Results
PGRS analysis
Here, we utilised PGRS analysis to determine whether
our ADHD cohort replicated the published ADHD
genetic risk proﬁle. Logistic regression was used to
examine the relationship between PGRS for each of the 5
major psychiatric disorders and ADHD case–control
status, for 1000 pT values ranging from 0.0005 to 0.5. Age,
gender, age2, age × gender, along with the top ﬁve eigen-
vectors accounting for population stratiﬁcation were used
as covariates. As expected, only ADHD PGRS was sig-
niﬁcantly predictive of ADHD case–control status
(Nagelkerke’s R2= 0.03, p= 7.6E−15 at pT= 0.0785).
PGRS for the other four psychiatric disorders did not
reach the recommended statistical signiﬁcance threshold
of p= 0.001at any p-threshold (Figure 1)34. The best
model ﬁt values for the remaining four psychiatric
disorders were as follows: BP (Nagelkerke’s R2= 0.00285,
p= 0.012, pT= 0.011), MDD (Nagelkerke’s R
2= 0.00250,
p= 0.018, pT= 0.103), ASD (Nagelkerke’s R
2= 0.00125,
p= 0.093, pT= 0.1), SCZ (Nagelkerke’s R
2= 0.00082, p=
0.175, pT= 0.0335).
ADHD case–control genome-wide association analysis
The Q–Q plot for the association analysis in 480 ADHD
cases and 1208 controls showed a slight inﬂation of p
values (λ= 1.08) relative to expectation under the
null distribution (Fig. 2). This lies within acceptable limits
(λ= 1.01–1.11) and the distribution is skewed at the
extreme tail of low p values, as expected. As can be seen
from the Manhattan plot (Fig. 3) and Table 1, a signiﬁcant
association between ADHD and rs6686722, mapped
22.8 kbp upstream of Tenascin R gene (TNR), was
observed (p= 3.15E−08). The imputation quality of
Fig. 1 Diagrammatic representation showing the polygenic risk
scores (PGRS) for ADHD, BP, MDD, ASD and SCZ against the
ADHD case–control statues for the current cohort. Only
ADHD–PGRS were signiﬁcantly predictive of ADHD status (p= 7.6 ×
10−15) explaining 3.25% of variance in the ADHD case–control status
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rs6686722 is very high (r2= 0.98). Interestingly, and as
presented in the regional association plot (Fig. 4), ten
SNPs within this region were either signiﬁcantly asso-
ciated with ADHD or showed a strong trend towards
statistical association, with p values⩽ 3.48E−07.
Three other genomic loci also showed strong trends
towards association (p values ranging from 9.647E−07 to
4.06E−07; Table 1). The ﬁrst of these is rs2410116 (p=
4.06E−07), which is mapped into a gene desert region
(Fig. 4) 300.2 kbp upstream of the gene encoding Rho
GTPase Activating Protein (also known as deleted in liver
cancer; DLC1). The second SNP is rs61975260 (p=
5.972E−07), which is mapped to the spermatogenesis
associated 7 gene (SPATA7). This suggestive association
signal is located within a subregion of Chr14
(88788507–89355721) that comprises several genes
including SPATA7, ZC3H14, PTPN21, EML5 and TTC8.
Some of these genes, such as SPATA7 have been impli-
cated in psychiatric conditions, including schizophrenia.
The third of these SNPs is rs77224013 (p= 9.647E−07)
which is mapped 58.4 kbp upstream of the Interferon
Alpha and Beta Receptor Subunit 2 gene (IFNAR2). This
region of the genome is enriched for genes that function
in the immune system (Fig. 4). In addition to the above
SNPs, 108 other genomic variants displayed suggestive
evidence of association (Table 1 and Supplementary Table
1) with p values⩽ 9.91E−05 to 1.0E−06. We also
explored replication of our results within the publically
available database of the PGC-iPSYCH meta-analysis25.
Supplementary Table 1 lists the comparable p value
within the PGC-iPSYCH meta-analysis against SNPs with
p values⩽ 9.91E−05 in the current dataset. Notably,
our leading SNP rs6686722 tends towards a nominally
signiﬁcant association in the PGC-iPSCYH meta-analysis
(p= 0.07). Further, ﬁve SNPs from the current study were
nominally signiﬁcant in the PGC-iPSYCH meta-analysis
(Supplementary Table 1).
Discussion
Here, we report the results of a GWAS of 480 probands
with childhood ADHD and 1208 controls. PGRS analysis
revealed that our sample replicated the published genetic
risk proﬁle for ADHD. In fact, PGRS of ADHD, but not
other major psychiatric disorders (ASD, SCZ, BP and
MDD), explained 3.25% of variance in ADHD
case–control status in our cohort (p= 7.6E−15). These
data demonstrate that the current dataset is enriched for
Fig. 2 Q–Q plot of ADHD–GWAS using 5,407,269 imputed SNPs A
deviation in the observed p-value at the top end consistent with
genetic inﬂuence
Fig. 3 Manhattan plot of the ADHD–GWAS showing −10 log (p value) versus genomic location for autosomal chromosomes (1–22). Results
show a signiﬁcant association of rs6686722 on chromosome 1 (p= 3.1E−08). The horizontal blue and orange lines represent p values at 1.0 × 1E−05
and 5.0E−08, respectively
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genetic risk for ADHD and thus makes a worthwhile
contribution to the international GWAS effort.
Genome-wide association analysis further revealed a
signiﬁcant association with rs6686722 that survived
the stringent GWAS correction for multiple comparisons
(p= 3.15E−08). This SNP is located 22.8 kbp upstream of
the Tenascin R (TNR) gene. The TNR gene is a member of
the Tenascin family of the neural extracellular matrix
glycoproteins and is highly expressed in the central ner-
vous system39. TNR is known to function in biological
processes such as neural cell adhesion, neurite outgrowth
and modulation of sodium channel function39,40 that have
been implicated in the aetiology of psychiatric disorders.
In addition, TNR interacts with Fibronectin 1 (FN1), the
latter being involved in cell adhesion and migration pro-
cesses including embryogenesis. This interaction may
modulate the adhesive properties of TNR during synapse
maintenance, a process that is suggested as a risk
mechanism for complex psychiatric disorders41. More-
over, genetic association studies have implicated the
genomic region where TNR is located in several brain
disorders including schizophrenia, Alzheimer’s disease,
narcolepsy and neurological sleep disorder42. Further, an
additional SNP (rs875326) mapped 2.5 kbp at the 3′
untranslated region of the TNR was reported to margin-
ally associate with drug response in schizophrenia43.
Although indirect, our TNR ADHD–GWAS ﬁnding,
combined with ﬁndings reported for other psychiatric
disorders, provides tentative support for a role of TNR in
the aetiology of psychiatric conditions.
The second top SNP in our ADHD–GWAS analysis is
mapped 300.2 kbp upstream of the Rho GTPase Activat-
ing Protein (also known as DLC1). Recent studies have
revealed common genetic susceptibilities to ADHD and
smoking behaviour44. Adults with ADHD have higher
rates of substance abuse, including higher rates of tobacco
smoking44. In this context, a recent GWAS analysis of
nicotine dependence reported genome-wide signiﬁcant
association with rs289519 (mapped to DLC1)45. Analysis
of rare CNVs across two independent studies of ASD46,47,
identiﬁed rare exonic loss within DLC1 as risk variants for
the disorder. Speciﬁcally, Prasad et al.46 identiﬁed one
ASD individual who possessed a rare CNV deletion of
22 kbp across a non-speciﬁed exonic region of DLC1.
Furthermore, Woodbury-Smith et al.47 identiﬁed a 25 kbp
deletion encompassing exon nine on DLC1 in two
Table 1 Results of the ADHD case–control genome-wide statistical association analysis for the top 20 SNPs
Chr SNP BP A1* OR L95 U95 p Value Nearest gene
1 rs6686722 175733963 T 0.4167 0.3056 0.5682 3.15E−08 22.8 kbp upstream of TNR
8 rs2410116 13673447 A 0.4991 0.3814 0.6531 4.06E−07 300.2 kbp upstream of DLC1
14 rs61975260 88895941 G 0.494 0.3745 0.6516 5.97E−07 SPATA7
21 rs77224013 34543845 A 3.869 2.252 6.647 9.64E−07 58.4 kbp upstream of IFNAR2
4 rs28612433 25264373 T 0.5385 0.4202 0.6902 1.01E−06 PI4K2B
15 rs4778174 27969566 A 0.5353 0.4164 0.6881 1.07E−06 30.5 kbp downstream of OCA2
19 rs35624673 8134616 T 0.5497 0.4299 0.7029 1.83E−06 FBN3
21 rs2015560 26028890 G 0.3596 0.2362 0.5475 1.86E−06 –
11 rs10767556 26623713 G 2.029 1.509 2.728 2.80E−06 ANO3
11 rs28609353 55651658 C 0.4698 0.3411 0.6471 3.74E−06 TRIM51
2 rs4673294 205189083 G 0.5462 0.4209 0.7089 5.43E−06 221.5 kbp upstream of PARD3B
21 rs112686226 34527379 G 2.903 1.831 4.602 5.78E−06 74.9 kbp upstream of IFNAR2
8 rs13439086 8374246 C 2.162 1.549 3.018 5.91E−06 198.9 kbp upstream of SGK223
13 rs9545903 82446913 C 1.747 1.37 2.228 6.91E−06 –
1 rs1172198 205662718 A 1.699 1.344 2.149 9.53E−06 SLC45A3/NUCKS1
9 rs7035982 27417407 A 1.757 1.368 2.257 1.01E−05 MOB3B
9 rs35289513 18263813 G 3.038 1.854 4.978 1.03E−05 210.3 kbp upstream of ADAMTSL1
6 rs4615440 963496 G 1.781 1.378 2.302 1.05E−05 LOC285768
3 rs938524 136521208 G 0.5791 0.4538 0.739 1.13E−05 SLC35G2/STAG1
18 rs2733140 28363540 T 0.5769 0.4511 0.7378 1.18E−05 250.2 kbp downstream DSC3
Chr chromosome, BP base pair position, * Allele 1, OR dds ratio, L95 lower conﬁdence intervals, U95 upper conﬁdence intervals, – gene desert region,
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unrelated ASD-affected individuals. The above lines of
evidence suggest that DLC1 is a candidate gene worthy of
further investigation as a potential susceptibility locus for
ADHD and its comorbid disorders (either ASD or sub-
stance abuse).
An additional subthreshold association with ADHD was
observed for rs61975260 (p= 5.972E−07) of the sper-
matogenesis associated 7 (SPATA7) gene which is
expressed in the retina and cerebellum. This gene func-
tions in the localisation of retinitis pigmentosa GTPase
regulator interacting protein 1 to the photoreceptor
connecting cilium (CC), as well as protein trafﬁcking
across the CC. Processing speed is a cognitive function
that is compromised in psychiatric conditions including
ADHD48,49. In this context, GWAS analysis49 of infor-
mation processing speed measured using digit symbol,
simple reaction time (RT), and 2 and 4-choice RT showed
suggestive evidence of association between DNA variation
in SPATA7 and 2-choice RT (p= 2.71E−06).
Finally, suggestive evidence of association between
ADHD and rs77224013 (9.65E−07) was also observed.
Rs77224013 is located 58.4 and 94.8 kbp upstream of the
immune cytokine receptors interferon alpha and beta
receptor subunit 2 (IFNAR2) and interleukin 10 receptor
subunit beta (IL10RB), respectively. Other immune
modulator genes such as IL10RB-As1 and IFNAR1 also
map to this region. Immune imbalance has been sug-
gested as a predisposing factor for ADHD in genetically
susceptible individuals50. Signiﬁcantly increased trans-
mission of IL-1Ra 4-repeat allele and decreased trans-
mission of 2-repeat allele of a variable number tandem
repeat polymorphism to ADHD-affected children was
reported by Segman et al.51 Further, immune dysregula-
tion is supported by the ﬁnding that ADHD individuals
have four times higher concentrations of Interleukins (IL-
1 and IL-6) than typically developing children52. This led
Verlaet et al.50 to hypothesise that “overproduction of
these cytokines could lead to chronic inﬂammation in
brain tissues”. This is consistent with brain anomalies in
children with ADHD. For example, Nopoulous et al.53
reported increased frequency of gray-matter heterotropia
(ectopic nodules of neurons) and posterior fossa
abnormalities in ADHD patients compared to controls.
Further, reduced cortical volume associated with reduced
Fig. 4 Regional association plots showing the four top GWAS SNPs in ADHD. The most signiﬁcant SNPs a (rs6686722), b (rs2410116),
c (rs61975260) and d (rs77224013) are presented as purple diamonds. Genetic recombination rates (cM/Mb) are shown with blue lines (spike)
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surface area and gyriﬁcation were also reported in ADHD
compared to controls54. However, the correlation between
overproduction of cytokines and brain anomalies in
ADHD requires further evidence to establish a causal link.
Our sample has provided replication evidence for some
of the results arising from the recent and largest ADHD
meta-analysis by the PGC-IPSYCH consortia25. For
example, we report a nominal association with rs281324
(p= 0.045), mapped to intron 3 of semaphorin 6D
(SEMA6D) gene which sits within 70 kbp genomic region
of signiﬁcant LD. Members of the semaphorin gene family
have been implicated as inhibitors or chemo-repellents in
axon pathﬁnding and fasciculation and branching. More
recently, Klein et al.55, examined if the genetic risk mar-
kers (reported by the PGC meta-analysis) mediate
alteration in brain structure. They observed that rs281323
(in perfect LD with rs281324) is signiﬁcantly associated
with increased risk for ADHD and putamen volume.
Further, the SEMA6D rs281323 is strongly associated
with the expression level of SEMA6D55. Together, these
ﬁnding clearly implicate SEMA6D as a susceptibility locus
for ADHD.
Finally, it is important to emphasise that our study has a
number of major limitations. First, the discovery sample is
small and has limited statistical power to detect a reliable
genome-wide association signal. Further, our leading SNP
association for TNR (rs6686722) is not signiﬁcant within
the much larger PGC-IPSYCH meta-analysis of ADHD
(p= 0.07). Notwithstanding these limitations, our ADHD
cohort is clearly enriched for genetic risk for ADHD, as
evinced by our strong PGRS results for ADHD (but not
the other major psychiatric disorders). As such, our study
therefore makes an important contribution to the inter-
national genetics effort for ADHD.
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